My understanding.
C.diff trial was underway in Israel, it was terminated primarily due to recruitment issues. Additional sites were to be opened to allow the trial to continue however this idea appears to have been abandoned in favour of exploring IMM-529's efficacy re. Recurrent C.diff.
The year ahead should be promising.
